Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.
Market Access Women's health: Predictions for 2026 A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.
Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform
Market Access Sustaining the mature product portfolio through strategic ou... Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.
Market Access Consolidating data strategy for global success: Insights fro... At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.